Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

1(16.7%)

N/A

1(16.7%)

Phase 4

1(16.7%)

6Total

Phase 3(3)

Phase 2(1)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05362760Phase 4Recruiting

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

Role: lead

NCT05658172Not ApplicableRecruiting

Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer

Role: lead

NCT06643585Phase 3Recruiting

A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

Role: lead

NCT02035813Phase 2Completed

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Role: lead

NCT02344472Phase 3Active Not Recruiting

Detect V / CHEVENDO (Chemo vs. Endo)

Role: lead

NCT01619111Phase 3Completed

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Role: lead

All 6 trials loaded